Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.

Journal Article (Journal Article;Multicenter Study)

IMPORTANCE: Platelets represent a potential therapeutic target for improved clinical outcomes in patients with COVID-19. OBJECTIVE: To evaluate the benefits and risks of adding a P2Y12 inhibitor to anticoagulant therapy among non-critically ill patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS: An open-label, bayesian, adaptive randomized clinical trial including 562 non-critically ill patients hospitalized for COVID-19 was conducted between February 2021 and June 2021 at 60 hospitals in Brazil, Italy, Spain, and the US. The date of final 90-day follow-up was September 15, 2021. INTERVENTIONS: Patients were randomized to a therapeutic dose of heparin plus a P2Y12 inhibitor (n = 293) or a therapeutic dose of heparin only (usual care) (n = 269) in a 1:1 ratio for 14 days or until hospital discharge, whichever was sooner. Ticagrelor was the preferred P2Y12 inhibitor. MAIN OUTCOMES AND MEASURES: The composite primary outcome was organ support-free days evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and, for those who survived to hospital discharge, the number of days free of respiratory or cardiovascular organ support up to day 21 of the index hospitalization (range, -1 to 21 days; higher scores indicate less organ support and better outcomes). The primary safety outcome was major bleeding by 28 days as defined by the International Society on Thrombosis and Hemostasis. RESULTS: Enrollment of non-critically ill patients was discontinued when the prespecified criterion for futility was met. All 562 patients who were randomized (mean age, 52.7 [SD, 13.5] years; 41.5% women) completed the trial and 87% received a therapeutic dose of heparin by the end of study day 1. In the P2Y12 inhibitor group, ticagrelor was used in 63% of patients and clopidogrel in 37%. The median number of organ support-free days was 21 days (IQR, 20-21 days) among patients in the P2Y12 inhibitor group and was 21 days (IQR, 21-21 days) in the usual care group (adjusted odds ratio, 0.83 [95% credible interval, 0.55-1.25]; posterior probability of futility [defined as an odds ratio <1.2], 96%). Major bleeding occurred in 6 patients (2.0%) in the P2Y12 inhibitor group and in 2 patients (0.7%) in the usual care group (adjusted odds ratio, 3.31 [95% CI, 0.64-17.2]; P = .15). CONCLUSIONS AND RELEVANCE: Among non-critically ill patients hospitalized for COVID-19, the use of a P2Y12 inhibitor in addition to a therapeutic dose of heparin, compared with a therapeutic dose of heparin only, did not result in an increased odds of improvement in organ support-free days within 21 days during hospitalization. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04505774.

Full Text

Duke Authors

Cited Authors

  • Berger, JS; Kornblith, LZ; Gong, MN; Reynolds, HR; Cushman, M; Cheng, Y; McVerry, BJ; Kim, KS; Lopes, RD; Atassi, B; Berry, S; Bochicchio, G; de Oliveira Antunes, M; Farkouh, ME; Greenstein, Y; Hade, EM; Hudock, K; Hyzy, R; Khatri, P; Kindzelski, A; Kirwan, B-A; Baumann Kreuziger, L; Lawler, PR; Leifer, E; Lopez-Sendon Moreno, J; Lopez-Sendon, J; Luther, JF; Nigro Maia, L; Quigley, J; Sherwin, R; Wahid, L; Wilson, J; Hochman, JS; Neal, MD; ACTIV-4a Investigators,

Published Date

  • January 18, 2022

Published In

Volume / Issue

  • 327 / 3

Start / End Page

  • 227 - 236

PubMed ID

  • 35040887

Pubmed Central ID

  • PMC8767444

Electronic International Standard Serial Number (EISSN)

  • 1538-3598

Digital Object Identifier (DOI)

  • 10.1001/jama.2021.23605


  • eng

Conference Location

  • United States